S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
Are These Consumer Staples Too Cheap for Investors To Ignore?
Is Gold Really Boring? (Ad)
A small venture capital player becomes a symbol in the fight over corporate diversity policies
Markets Are Loving These Stocks 'Firing On All Cylinders'
Is Gold Really Boring? (Ad)
Etsy Gets an Upgrade and $100 Target...Is the Bottom Finally In?
'Enough Venom to Fill a Martini Glass and Kill 5 People': An Amazon Driver Was Bitten By a Rattlesnake on the Job in Florida
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
Are These Consumer Staples Too Cheap for Investors To Ignore?
Is Gold Really Boring? (Ad)
A small venture capital player becomes a symbol in the fight over corporate diversity policies
Markets Are Loving These Stocks 'Firing On All Cylinders'
Is Gold Really Boring? (Ad)
Etsy Gets an Upgrade and $100 Target...Is the Bottom Finally In?
'Enough Venom to Fill a Martini Glass and Kill 5 People': An Amazon Driver Was Bitten By a Rattlesnake on the Job in Florida
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
Are These Consumer Staples Too Cheap for Investors To Ignore?
Is Gold Really Boring? (Ad)
A small venture capital player becomes a symbol in the fight over corporate diversity policies
Markets Are Loving These Stocks 'Firing On All Cylinders'
Is Gold Really Boring? (Ad)
Etsy Gets an Upgrade and $100 Target...Is the Bottom Finally In?
'Enough Venom to Fill a Martini Glass and Kill 5 People': An Amazon Driver Was Bitten By a Rattlesnake on the Job in Florida
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
Are These Consumer Staples Too Cheap for Investors To Ignore?
Is Gold Really Boring? (Ad)
A small venture capital player becomes a symbol in the fight over corporate diversity policies
Markets Are Loving These Stocks 'Firing On All Cylinders'
Is Gold Really Boring? (Ad)
Etsy Gets an Upgrade and $100 Target...Is the Bottom Finally In?
'Enough Venom to Fill a Martini Glass and Kill 5 People': An Amazon Driver Was Bitten By a Rattlesnake on the Job in Florida
NASDAQ:ATHE

Alterity Therapeutics (ATHE) Stock Forecast, Price & News

$2.68
+0.11 (+4.29%)
(As of 09/20/2023 ET)
Compare
Today's Range
$2.68
▼
$2.68
50-Day Range
$2.56
▼
$2.95
52-Week Range
$2.52
▼
$5.10
Volume
341 shs
Average Volume
2,519 shs
Market Capitalization
$10.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00
ProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Alterity Therapeutics MarketRank™ Forecast

Analyst Rating
0.00 Rating Score
Upside/​Downside
273.8% Upside
$10.00 Price Target
Short Interest
Healthy
0.43% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.52) to ($0.29) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.90 out of 5 stars

Medical Sector

676th out of 961 stocks

Pharmaceutical Preparations Industry

317th out of 453 stocks

See Top Rated MarketRank™ Stocks Here

ATHE stock logo

About Alterity Therapeutics (NASDAQ:ATHE) Stock

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

ATHE Price History

ATHE Stock News Headlines

August 31, 2023 | finance.yahoo.com
Alterity Therapeutics Presents New Data on Multiple System Atrophy, a Rare Parkinsonian Disorder
August 23, 2023 | finance.yahoo.com
Alterity Therapeutics Granted New Composition of Matter Patent in Europe for Neurodegenerative Diseases including Parkinson’s and Alzheimer’s
September 21, 2023 | Edge On The Street (Ad)
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
August 22, 2023 | technews.tmcnet.com
Alterity Therapeutics Rare Disease Natural History Study to be Featured at the International Congress of Parkinson's Disease and Movement Disorders
August 22, 2023 | finance.yahoo.com
Alterity Therapeutics Rare Disease Natural History Study to be Featured at the International Congress of Parkinson’s Disease and Movement Disorders
August 15, 2023 | finance.yahoo.com
Alterity Therapeutics Receives a $4.74 million Research & Development Tax Incentive Refund
July 31, 2023 | finance.yahoo.com
Appendix 4C – Q4 FY23 Quarterly Cash Flow Report
July 26, 2023 | finance.yahoo.com
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned
September 21, 2023 | Edge On The Street (Ad)
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
June 21, 2023 | finance.yahoo.com
Alterity Therapeutics to Present in MST Access Rare Diseases, Rich Returns Forum on 22 June 2023
May 30, 2023 | finance.yahoo.com
Alterity Therapeutics Initiates Second Phase 2 Study in Rare Parkinsonian Disorder
May 19, 2023 | finance.yahoo.com
Alterity Therapeutics CEO David Stamler to Present at the SHARE Series Monday Management Update on Monday, May 22, 2023
May 10, 2023 | finance.yahoo.com
Appendix 4C – Q3 FY23 Quarterly Cash Flow Report
May 10, 2023 | finance.yahoo.com
Alterity Therapeutics Enrolls First Patient in Australia in ATH434 Global Phase 2 Clinical Trial in Multiple System Atrophy
April 26, 2023 | finance.yahoo.com
Alterity Therapeutics Presents Promising Wearable Sensor Data from the bioMUSE Natural History Study at the American Academy of Neurology
March 14, 2023 | msn.com
Alterity gets US patent, inks licensing pact to advance asset for Alzheimer's
March 14, 2023 | finance.yahoo.com
Alterity Therapeutics Announces Granting of New Composition of Matter Patent and Exclusive License Agreement for Assets in Alzheimer’s Disease
March 8, 2023 | finance.yahoo.com
Alterity Therapeutics Enrolls First Patient in Italy in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
January 31, 2023 | finance.yahoo.com
Appendix 4C - Q2 FY23 Quarterly Cash Flow Report
January 30, 2023 | finance.yahoo.com
Alterity's Parkinson's Candidate Prevents Loss Of Brain Cells In Animal Model
January 30, 2023 | msn.com
Alterity stock rises ~10% as ATH434 shows promise in Parkinson’s animal model study
January 30, 2023 | technews.tmcnet.com
Alterity's ATH434 Prevents Loss of Brain Cells in Parkinson's Disease Animal Model
January 30, 2023 | finance.yahoo.com
Alterity’s ATH434 Prevents Loss of Brain Cells in Parkinson’s Disease Animal Model
January 25, 2023 | finance.yahoo.com
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Italy for the Treatment of Individuals with Multiple System Atrophy
January 9, 2023 | finance.yahoo.com
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy
January 7, 2023 | msn.com
Alterity Therapeutics to implement 1-for-10 reverse ADS split
January 6, 2023 | finance.yahoo.com
Alterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation)
See More Headlines
Receive ATHE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alterity Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ATHE Company Calendar

Today
9/21/2023
Fiscal Year End
6/30/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ATHE
CUSIP
N/A
CIK
1131343
Web
www.alteritytherapeutics.com
Phone
(139) 349-4906
Fax
61-3-9348-0377
Employees
12
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.00
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+273.8%
Consensus Rating
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.17
Quick Ratio
6.17

Sales & Book Value

Annual Sales
$3.37 million
Price / Sales
3.18
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.83 per share
Price / Book
0.70

Miscellaneous

Outstanding Shares
4,010,000
Free Float
2,455,000
Market Cap
$10.73 million
Optionable
Not Optionable
Beta
1.16
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover
10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Geoffrey Paul Kempler B.Sc (Age 68)
    B.Sc., Co-Founder & Non-Exec. Chairman
    Comp: $251.22k
  • Dr. David A. Stamler M.D. (Age 62)
    Chief Exec. Officer
    Comp: $426.52k
  • Ms. Kathryn J. E. Andrews (Age 56)
    Chief Financial Officer
    Comp: $212k
  • Dr. Rudolph Emile Tanzi Ph.D. (Age 64)
    Chief Scientific Advisor and Member of R&D Advisory Board
  • Dr. Steven D. Targum
    Chief Medical Advisor
  • Dr. Robert Cherny
    Head of Research
  • Mr. Phillip Allen Hains BBus(Acc) (Age 64)
    C.A., CA, M.B.A., MBA, Company Sec.

Key Competitors

View All Competitors













ATHE Stock - Frequently Asked Questions

What is Alterity Therapeutics' stock price forecast for 2023?

0 brokerages have issued 12-month target prices for Alterity Therapeutics' shares. Their ATHE share price forecasts range from $10.00 to $10.00. On average, they predict the company's stock price to reach $10.00 in the next year. This suggests a possible upside of 273.8% from the stock's current price.
View analysts price targets for ATHE or view top-rated stocks among Wall Street analysts.

How have ATHE shares performed in 2023?

Alterity Therapeutics' stock was trading at $3.4820 at the beginning of 2023. Since then, ATHE stock has decreased by 23.2% and is now trading at $2.6750.
View the best growth stocks for 2023 here.

Are investors shorting Alterity Therapeutics?

Alterity Therapeutics saw a decrease in short interest during the month of August. As of August 31st, there was short interest totaling 16,700 shares, a decrease of 13.0% from the August 15th total of 19,200 shares. Based on an average daily volume of 4,300 shares, the short-interest ratio is currently 3.9 days. Approximately 0.4% of the company's stock are sold short.
View Alterity Therapeutics' Short Interest.

When did Alterity Therapeutics' stock split?

Alterity Therapeutics shares reverse split on Monday, January 9th 2023. The 1-10 reverse split was announced on Monday, January 9th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 9th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Alterity Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alterity Therapeutics investors own include Achillion Pharmaceuticals (ACHN), Aurora Cannabis (ACB), ACADIA Pharmaceuticals (ACAD), Arbutus Biopharma (ABUS), Abacus Property Group (ABP), Advanced BioMedical Technologies (ABMT), Abiomed (ABMD), ARCA biopharma (ABIO), Abeona Therapeutics (ABEO) and Abcam (ABCZY).

What is Alterity Therapeutics' stock symbol?

Alterity Therapeutics trades on the NASDAQ under the ticker symbol "ATHE."

How do I buy shares of Alterity Therapeutics?

Shares of ATHE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alterity Therapeutics' stock price today?

One share of ATHE stock can currently be purchased for approximately $2.68.

How much money does Alterity Therapeutics make?

Alterity Therapeutics (NASDAQ:ATHE) has a market capitalization of $10.73 million and generates $3.37 million in revenue each year.

How can I contact Alterity Therapeutics?

Alterity Therapeutics' mailing address is LEVEL 3 460 BOURKE STREET, MELBOURNE C3, VIC 3000. The official website for the company is www.alteritytherapeutics.com. The company can be reached via phone at (139) 349-4906, via email at alterity@we-buchan.com, or via fax at 61-3-9348-0377.

This page (NASDAQ:ATHE) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -